West Pharmaceutical Services Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −1.54%.
Did WST Beat Earnings? Q4 2025 Results
West Pharmaceutical Services closed out fiscal 2025 on a strong note, posting Q4 adjusted diluted EPS of $2.04, beating the $1.83 consensus estimate by 11.48%, as revenue climbed 7.5% year-over-year to $805.00 million. The standout driver was a 15.1% organic surge in High-Value Product Components, fueled by demand for Westar and Envision products, while GLP-1-related revenues proved a meaningful contributor, with elastomers alone accounting for 10% of total company sales in the quarter. Gross margin expanded 130 basis points to 37.8%, and adjusted diluted EPS grew 12.1% versus the prior-year period. For the full year, free cash flow jumped 69.6% to $468.90 million, a performance strong enough to support a newly authorized $1 billion share repurchase program alongside a quarterly dividend of $0.22 per share. Looking ahead, management guided fiscal 2026 net sales of $3.21 billion to $3.27 billion and adjusted EPS of $7.85 to $8.20, representing earnings growth of 7.7% to 12.5%, with Contract Manufacturing margins expected to recover to historical levels as early as Q1 2026.
- Double-digit organic growth in HVP Components driven by Westar and Envision products
- GLP-1 elastomers represented 10% of total company revenues in Q4
- GLP-1 Contract Manufacturing revenues represented 7% of total company revenues in Q4
- Biologics market group accounted for 42% of Q4 revenue
- Favorable foreign currency translation contributed 4.2 percentage points to Q4 revenue growth
- EMEA region led geographic growth at 14.6% year-over-year
“Our strong finish to 2025 was a result of the team's relentless execution of our growth strategy. Our performance in the quarter was led by our High-Value Product Components business in our Proprietary Products Segment, enabling us to deliver double-digit adjusted earnings per share growth. We expect positive momentum to continue in 2026, which will be a key year of execution and operational excellence to drive sustainable growth and create value for our patients, customers and shareholders.”
West Pharmaceutical Services CEO, on the earnings call
Forward Guidance & Outlook
For fiscal 2026, West expects net sales of $3.215 billion to $3.275 billion, representing reported growth of 4.6% to 6.5% and organic growth of approximately 5% to 7%. Full-year 2026 adjusted diluted EPS is expected to be $7.85 to $8.20, representing growth of 7.7% to 12.5%. Guidance assumes a mid-year 2026 close for the SmartDose 3.5mL sale to AbbVie and includes an estimated 2 percentage point full-year benefit from current foreign currency exchange rates. Capital expenditures are expected to be $250 million to $275 million. For Q1 2026, net sales are expected to be $770 million to $790 million with adjusted diluted EPS of $1.65 to $1.70. Contract Manufacturing operating margins are expected to return to historical levels in Q1 2026 following remediation of a temporary Arizona facility disruption.
WST YoY Financials
WST Revenue by Segment
WST Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.